Hcw Biologics, Inc. (HCWB)
NASDAQ:HCWB
Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$3.99
-$0.02(-4.12%)
At close: 4:00 PM EST
$3.99
-$0.02(-4.12%)
Day’s Range― - ―
52-Week Range$0.25 - $7.35
Previous CloseN/A
Volume102.01K
Average Volume (3M)25.70M
Market Cap
$12.05M
Enterprise Value$9.48M
Total Cash (Recent Filing)$1.23M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 07, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.61
Shares Outstanding6,734,104
10 Day Avg. Volume26,375,546
30 Day Avg. Volume25,697,452
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.54
P/FCF Ratio-0.15
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.45
Enterprise Value/Ebitda-8.98
Forecast
1Y Price Target
$5.00Price Target Upside25.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Revenue ReboundA sharp TTM revenue rebound to roughly $6.6M combined with an unusually high ~97% gross margin indicates strong unit economics for recognized revenue. Durable margin strength supports attractive economics for licensing, partnerships, and scalable clinical/commercial models if pipeline assets progress.
Improving Leverage And Positive EquityMaterial improvement in leverage and a return to positive equity reduce short-term insolvency risk and improve financial flexibility. Lowered leverage enhances the company's ability to negotiate non-dilutive deals or bridge financings while advancing costly clinical programs over the next several quarters.
Regained Cell-therapy Rights; Strategic CAR-T/NK PositioningReclaiming commercial-ready reagents and IP for HCW9201/9206 restores direct control over high-value cell therapy inputs. Demonstrated GMP-scale production and T-memory stem cell enrichment positions HCW to capture manufacturing partnerships and licensing revenue in the growing CAR-T/NK supply chain.
Bears Say
Severe Cash Burn And Negative Free Cash FlowSustained ~-$11.5M TTM operating and free cash flow signals heavy ongoing cash consumption. This persistent burn forces reliance on external financing, increasing dilution risk and creating funding-dependency that can constrain R&D pacing and strategic optionality over the medium term.
Large Operating Losses And Weak ProfitabilityAn EBIT margin near -77% and continued net losses show the business has not demonstrated path to self-sustaining profitability. Persistent operating deficits imply lengthy reliance on capital markets and limit the company's ability to fund late-stage development without recurring partner or investor support.
Ongoing Nasdaq Listing Risk And Regulatory OversightContinued listing conditionality and a one-year monitoring regime increase execution risk for capital raises and corporate actions. Heightened oversight can complicate fundraising timing, investor relations, and strategic transactions, and creates a persistent compliance overhang during the next several quarters.
HCW Biologics News
HCWB FAQ
What was Hcw Biologics, Inc.’s price range in the past 12 months?
Hcw Biologics, Inc. lowest stock price was $0.25 and its highest was $7.35 in the past 12 months.
What is Hcw Biologics, Inc.’s market cap?
Hcw Biologics, Inc.’s market cap is $12.05M.
When is Hcw Biologics, Inc.’s upcoming earnings report date?
Hcw Biologics, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 64 days.
How were Hcw Biologics, Inc.’s earnings last quarter?
Hcw Biologics, Inc. released its earnings results on May 14, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of N/A by $0.37.
Is Hcw Biologics, Inc. overvalued?
According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Undervalued.
Does Hcw Biologics, Inc. pay dividends?
Hcw Biologics, Inc. does not currently pay dividends.
What is Hcw Biologics, Inc.’s EPS estimate?
Hcw Biologics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Hcw Biologics, Inc. have?
Hcw Biologics, Inc. has 6,734,104 shares outstanding.
What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?
Hcw Biologics, Inc. reported an EPS of $0.37 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 262.018%.
Which hedge fund is a major shareholder of Hcw Biologics, Inc.?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hcw Biologics, Inc.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$5.00
▲(25.31% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
13.02% Insiders
0.37% Mutual Funds
5.17% Other Institutional Investors
81.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---